Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The purpose of this study is to evaluate the safety and efficacy of lenvatinib (E7080/MK‐7902) in combination with pembrolizumab (MK‐3745) versus lenvatinib in combination with placebo as first‐line therapy for the treatment of advanced hepatocellular carcinoma in adult participants. The primary hypotheses of this study are that lenvatinib plus pembrolizumab is superior to lenvatinib plus placebo with respect to progression‐free survival (PFS) and overall survival (OS).
Epistemonikos ID: e801fafdb562fb37310925cc9b50724d0c685c94
First added on: May 21, 2024